Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2019

View Archived Issues

Staph toxins' DARC arts: Targeting blood vessels

Alternative energy for metabolic brain disorder

H3 Biomedicine publishes preclinical pharmacokinetics and metabolism data on H3B-6545

Imbrium Therapeutics and TetraGenetics collaborate to develop novel biologic therapeutics for pain

TG Therapeutics initiates first-in-human study of its anti-CD47/CD19 bispecific antibody TG-1801

Acetylation by aspirin can attenuate autoimmunity

LY-3295668 demonstrates efficacy in RB1mut cancer models

Eribulin liposomal formulation well tolerated in patients with solid tumors

Nicotinamide N-methyltransferase inhibitor enhances aged muscle regeneration

Prion protein-binding monoclonal antibodies synthesized at New York University

Northwestern University presents beta-glucocerebrosidase activators

Bristol-Myers Squibb discovers sphingosine 1-phosphate receptor 1 agonists

New PD-1/PD-L1 interaction inhibitors patented by ChemoCentryx

Southeast University describes antibodies targeting the HPV16 E6 oncoprotein

New generation of SARDs for the treatment of advanced prostate cancer

Targeting DEFA1/DEFA3 ameliorates sepsis severity in mice

Alkermes begins ARTISTRY 2 study of subcutaneous ALKS-4230 in advanced solid tumors

Grants to support evaluation of Radspherin in colorectal cancer

Immatics Biotechnologies and Roche to test IMA-101 plus Tecentriq in cancer

FunPep gains Australian clearance for phase I/IIa study of FPP-003

MHRA clears Nuformix to begin human pharmacokinetic studies with NXP-001

Immunic initiates phase II study of IMU-838 for relapsing-remitting MS

Eidos initiates pivotal phase III study of AG-10 in ATTR-CM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...